Metrics as of 10/16/2026, 07:40 PM (Berlin time), refresh in progress.
Aura Biosciences Stock
Aura Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Natalie C. Holles
- Employees
- 113
- Market cap
- $634 M
- IPO
- 29/10/2021
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically…
Aura Biosciences stock: price history
1D
-3.6%
1W
-6.5%
1M
-9.1%
6M
-16.1%
YTD
+12.2%
1Y
-1.2%
2Y
-40.3%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~50% stronger price swings than usual
Ask the agents about Aura Biosciences
Analyst assessment of Aura Biosciences
PRICE TARGET LOW
US$17.00
CONSENSUS
US$17.50
MEDIAN
US$17.50
PRICE TARGET HIGH
US$18.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 11/08/2026
Aura Biosciences stock metrics
P/E
-3.44
P/B
1.84
EV/EBITDA
-4.41
RETURN ON EQUITY
-14.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.2%
FLOAT SHARES
66,559,095
AVG. DAILY VOLUME (30D)
947,891
Insider transactions (SEC)
Person Julie
Kratz Erica
Abu-Absi Susan
Elazzouzi Amy
Hopkins Janet Jill
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.6%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Aura Biosciences stock
What does Aura Biosciences do?
Aura Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Natalie C. Holles, the company employs around 113 people.
The IPO was on 29/10/2021; the stock trades on NASDAQ under the ticker AURA.
What do analysts say about Aura Biosciences stock?
8 analysts rate the stock, the consensus is Buy (as of 11/08/2026).
The average price target is US$17.50, ranging from US$17.00 to US$18.00, with a median of US$17.50.
This is an external assessment, not a statement by Market Jury.
When does Aura Biosciences report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 50% stronger than usual.
Does Aura Biosciences pay a dividend?
No, Aura Biosciences currently does not pay a dividend.
Which stocks are comparable to Aura Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Aura Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aura Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.